Eli Lilly’s GLP-1 scale drives extraordinary top and bottom-line acceleration

Eli Lilly’s Q2 earnings beat showcased massive GLP-1 driven revenue expansion and margin leverage as blockbuster Mounjaro and Zepbound demand continues to redefine sector capital rotation expectations.